Strategic sale opportunity Major resilience in the market with announced strategic sale of chromatography business to Merck/MilliporeSigma, suggesting a potential partner or competitor shift that could prompt cross-sell opportunities in CDMO services, analytics, and bioprocessing solutions for life sciences customers.

ACME sustainability edge Sustainability initiatives with Polycarbin partnership reducing lab plastic waste indicate a value proposition for customers prioritizing green operations, enabling you to position lifecycle services and waste- minimization capabilities as differentiators.

OrganoidXplore traction Collaborative platform OrganoidXplore with Crown Bioscience signals strength in preclinical models; potential upsell of organoid-centric assays, early drug discovery services, and associated data analytics to biopharma clients accelerating preclinical timelines.

Global capabilities Global network of affiliates, R&D labs, and manufacturing facilities offers a doorway for enterprise buyers seeking integrated services across development stages, enabling cross-sell of end-to-end biopharma solutions to larger organizations.

Mid-market growth Revenue in the mid-range with a lean employee base presents an opportunity to target mid-sized biopharma and academic customers needing cost-efficient CDMO and materials innovation support, along with flexible partnerships and scalable capacity.